Pulmonary hypertension, despite advances in treatment, still has a poor prognosis, which is often associated with right heart failure, and for which pulmonary arterial hypertension (PAH) is a severe ...
The device has evolved from one aimed at just functional MR to a broader HF therapy. EMPOWER will provide more insights.
Gossamer Bio's Seralutinib shows promise for PAH and PH-ILD treatment. The main event comes with its topline results in Q4 ...
In PH models, Peli1 expression significantly increases in lung macrophages, and genetic deletion of Peli1 leads to decreased macrophage activation and reduced pulmonary artery remodeling in ...
The immune protein STAT6 may be a driver of pulmonary hypertension in people with obstructive sleep apnea, a study in mice ...
Pulmonary arterial hypertension is a disease of the pulmonary vasculature ... 30, 32 Recent evidence highlights a dynamic interaction between skeletal muscle and pulmonary vascular remodeling, ...
DelveInsight’s, “HDAC Inhibitor Pipeline Insight” report provides comprehensive insights about 40+ companies and 50+ pipeline ...
Titled “Targeting Fibroblast Activation Protein for Molecular Imaging of Fibrotic Remodeling in Pulmonary Arterial Hypertension,” the study was published in The Journal of Nuclear Medicine. PAH is ...
Figure 2 Possible dual roles of senescent endothelial cells in pulmonary arterial hypertension (PAH ... in the accumulation of senescent endothelial cells, contributing to arterial remodeling, ...
Pulmonary arterial hypertension invovles remodeling of the entire pulmonary arterial tree with narrowing of distal vessels driving up afterload on the right ventricle, leading to death or transplant.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback